Skip to main content
Top

25-04-2024 | Petechiae | Review

Dermatologic manifestations of hematologic disorders

Authors: Hannah L. King, Genevieve B. Benedetti, Jesse J. Keller, Thomas G. DeLoughery, Joseph J. Shatzel, Kylee L. Martens

Published in: Annals of Hematology

Login to get access

Abstract

Distinguishing key morphologic features and understanding the pathophysiology of common cutaneous manifestations of hematologic disorders is essential to ensure prompt and appropriate treatment. In fact, classic cutaneous signs may provide the first clue to the diagnosis of an underlying hematologic disease. Disorders of coagulation, vascular abnormalities, or cutaneous infiltration and deposition are responsible for the underlying pathophysiology of cutaneous manifestations in the majority of cases. Hematologists often feel ill-equipped in identifying morphologic changes in the skin. Thus, the purpose of this review is to provide a comprehensive overview of classic cutaneous manifestations and diagnostic considerations of the associated hematologic conditions. Though there is a specific focus on non-malignant disorders, those straddling the spectrum of malignancy are also discussed. In many disease states, the skin may serve as an important marker of an emerging hematologic disorder, so close collaboration and multidisciplinary input remain essential to provide optimal and timely care for these patients.
Literature
1.
go back to reference Li AW et al (2017) The skin as a window to the blood: cutaneous manifestations of myeloid malignancies. Blood Rev 31(6):370–388PubMedCrossRef Li AW et al (2017) The skin as a window to the blood: cutaneous manifestations of myeloid malignancies. Blood Rev 31(6):370–388PubMedCrossRef
2.
go back to reference Pande SY, Kharkar V (2014) Clinical profile of cutaneous manifestations with and without hematologic disease: a comparative study. Indian Dermatol Online J 5(2):138–143PubMedPubMedCentralCrossRef Pande SY, Kharkar V (2014) Clinical profile of cutaneous manifestations with and without hematologic disease: a comparative study. Indian Dermatol Online J 5(2):138–143PubMedPubMedCentralCrossRef
3.
go back to reference Maglie R et al (2020) Immune-mediated dermatoses in patients with Haematological malignancies: a Comprehensive Review. Am J Clin Dermatol 21(6):833–854PubMedPubMedCentralCrossRef Maglie R et al (2020) Immune-mediated dermatoses in patients with Haematological malignancies: a Comprehensive Review. Am J Clin Dermatol 21(6):833–854PubMedPubMedCentralCrossRef
4.
go back to reference Souza PK et al (2023) Dermatological manifestations of hematologic neoplasms. Part I: secondary specific skin lesions. Bras Dermatol 98(1):5–12CrossRef Souza PK et al (2023) Dermatological manifestations of hematologic neoplasms. Part I: secondary specific skin lesions. Bras Dermatol 98(1):5–12CrossRef
5.
go back to reference de Souza PK et al (2023) Dermatological manifestations of hematologic neoplasms. Part II: nonspecific skin lesions/paraneoplastic diseases. Bras Dermatol 98(2):141–158CrossRef de Souza PK et al (2023) Dermatological manifestations of hematologic neoplasms. Part II: nonspecific skin lesions/paraneoplastic diseases. Bras Dermatol 98(2):141–158CrossRef
6.
go back to reference Kaddis N, Fisher D, Jacobsen ED (2019) Cutaneous involvement of hematologic malignancies. Hematol Oncol Clin North Am 33(1):163–172PubMedCrossRef Kaddis N, Fisher D, Jacobsen ED (2019) Cutaneous involvement of hematologic malignancies. Hematol Oncol Clin North Am 33(1):163–172PubMedCrossRef
7.
go back to reference Fogo A, du Vivier A (2009) The cutaneous manifestations of haematological malignancy. Clin Med (Lond) 9(4):366–370PubMed Fogo A, du Vivier A (2009) The cutaneous manifestations of haematological malignancy. Clin Med (Lond) 9(4):366–370PubMed
8.
go back to reference Antonov D et al (2020) The rash that becomes purpuric, petechial, hemorrhagic, or ecchymotic. Clin Dermatol 38(1):3–18PubMedCrossRef Antonov D et al (2020) The rash that becomes purpuric, petechial, hemorrhagic, or ecchymotic. Clin Dermatol 38(1):3–18PubMedCrossRef
9.
10.
go back to reference McGrath A, Barrett MJ (2023) Petechiae, in StatPearls. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Michael Barrett declares no relevant financial relationships with ineligible companies McGrath A, Barrett MJ (2023) Petechiae, in StatPearls. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Michael Barrett declares no relevant financial relationships with ineligible companies
13.
go back to reference Whiting C, Azim SA, Friedman A (2024) What’s Old is New: an emerging focus on Dermatoporosis. J Drugs Dermatol 23(2):113–114PubMedCrossRef Whiting C, Azim SA, Friedman A (2024) What’s Old is New: an emerging focus on Dermatoporosis. J Drugs Dermatol 23(2):113–114PubMedCrossRef
14.
go back to reference Neutze D, Roque J (2016) Clinical evaluation of bleeding and bruising in primary care. Am Fam Physician 93(4):279–286PubMed Neutze D, Roque J (2016) Clinical evaluation of bleeding and bruising in primary care. Am Fam Physician 93(4):279–286PubMed
15.
go back to reference Modi AV (1992) Spontaneous bruising in a Family Practice Population: how common and how benign is it? Can Fam Physician 38:1805–1808PubMedPubMedCentral Modi AV (1992) Spontaneous bruising in a Family Practice Population: how common and how benign is it? Can Fam Physician 38:1805–1808PubMedPubMedCentral
16.
go back to reference Russell JP, Gibson LE (2006) Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol 45(1):3–13PubMedCrossRef Russell JP, Gibson LE (2006) Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol 45(1):3–13PubMedCrossRef
17.
go back to reference DeBiasio C et al (2022) Hypergammaglobulinemic purpura of Waldenstrom-unusual and impressive case in a patient with myeloma: a case report. SAGE Open Med Case Rep 10:2050313X221086321PubMedPubMedCentral DeBiasio C et al (2022) Hypergammaglobulinemic purpura of Waldenstrom-unusual and impressive case in a patient with myeloma: a case report. SAGE Open Med Case Rep 10:2050313X221086321PubMedPubMedCentral
18.
go back to reference Georgesen C, Fox LP, Harp J (2020) Retiform purpura: a diagnostic approach. J Am Acad Dermatol 82(4):783–796PubMedCrossRef Georgesen C, Fox LP, Harp J (2020) Retiform purpura: a diagnostic approach. J Am Acad Dermatol 82(4):783–796PubMedCrossRef
19.
go back to reference Goshua G, Bendapudi PK, Lee AI (2022) Thrombosis questions from the inpatient wards. Hematol Am Soc Hematol Educ Program 2022(1):481–490CrossRef Goshua G, Bendapudi PK, Lee AI (2022) Thrombosis questions from the inpatient wards. Hematol Am Soc Hematol Educ Program 2022(1):481–490CrossRef
20.
go back to reference Lamadrid-Zertuche AC, Garza-Rodríguez V, Ocampo-Candiani JJ (2018) Pigmented purpura and cutaneous vascular occlusion syndromes. Bras Dermatol 93(3):397–404CrossRef Lamadrid-Zertuche AC, Garza-Rodríguez V, Ocampo-Candiani JJ (2018) Pigmented purpura and cutaneous vascular occlusion syndromes. Bras Dermatol 93(3):397–404CrossRef
21.
go back to reference Bendapudi P et al (2020) Rare inherited defects of the complement system in Purpura Fulminans. Blood 136:35–36CrossRef Bendapudi P et al (2020) Rare inherited defects of the complement system in Purpura Fulminans. Blood 136:35–36CrossRef
22.
go back to reference Raife T, Paola JD (2004) Transfusion of the Pediatric Surgery, Trauma, and Intensive Care Unit Patient : pp. 137–148 Raife T, Paola JD (2004) Transfusion of the Pediatric Surgery, Trauma, and Intensive Care Unit Patient : pp. 137–148
24.
go back to reference Assan F et al (2022) Antiphospholipid-negative Sneddon’s syndrome: a comprehensive overview of a rare entity. Ann Dermatol Venereol 149(1):3–13PubMedCrossRef Assan F et al (2022) Antiphospholipid-negative Sneddon’s syndrome: a comprehensive overview of a rare entity. Ann Dermatol Venereol 149(1):3–13PubMedCrossRef
26.
go back to reference McCalmont CS et al (1992) Livedo vasculitis: vasculitis or thrombotic vasculopathy? Clin Exp Dermatol 17(1):4–8PubMedCrossRef McCalmont CS et al (1992) Livedo vasculitis: vasculitis or thrombotic vasculopathy? Clin Exp Dermatol 17(1):4–8PubMedCrossRef
27.
go back to reference Bilgic A et al (2021) Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management. Int J Womens Dermatol 7(5Part A):588–599PubMedPubMedCentralCrossRef Bilgic A et al (2021) Livedoid vasculopathy: a multidisciplinary clinical approach to diagnosis and management. Int J Womens Dermatol 7(5Part A):588–599PubMedPubMedCentralCrossRef
28.
29.
go back to reference Singh P, Schwartz RA (2020) Disseminated intravascular coagulation: a devastating systemic disorder of special concern with COVID-19. Dermatol Ther 33(6):e14053PubMedPubMedCentralCrossRef Singh P, Schwartz RA (2020) Disseminated intravascular coagulation: a devastating systemic disorder of special concern with COVID-19. Dermatol Ther 33(6):e14053PubMedPubMedCentralCrossRef
30.
go back to reference Robboy SJ et al (1973) The skin in disseminated intravascular coagulation. Prospective analysis of thirty-six cases. Br J Dermatol 88(3):221–229PubMedCrossRef Robboy SJ et al (1973) The skin in disseminated intravascular coagulation. Prospective analysis of thirty-six cases. Br J Dermatol 88(3):221–229PubMedCrossRef
31.
go back to reference Levi M (2014) Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol 36(3):228–236PubMedCrossRef Levi M (2014) Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol 36(3):228–236PubMedCrossRef
32.
go back to reference Chiasakul T, Cuker A (2018) Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol Am Soc Hematol Educ Program 2018(1):530–538CrossRef Chiasakul T, Cuker A (2018) Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol Am Soc Hematol Educ Program 2018(1):530–538CrossRef
33.
go back to reference Joly BS, Coppo P, Veyradier A (2017) Thromb Thrombocytopenic purpura Blood 129(21):2836–2846 Joly BS, Coppo P, Veyradier A (2017) Thromb Thrombocytopenic purpura Blood 129(21):2836–2846
34.
go back to reference George JN (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116(20):4060–4069PubMedCrossRef George JN (2010) How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 116(20):4060–4069PubMedCrossRef
36.
go back to reference Alves J et al (2012) Cutaneous thrombosis related to paroxysmal nocturnal hemoglobinuria: clinical report. Dermatol Online J 18(11):13PubMedCrossRef Alves J et al (2012) Cutaneous thrombosis related to paroxysmal nocturnal hemoglobinuria: clinical report. Dermatol Online J 18(11):13PubMedCrossRef
37.
go back to reference Hill A, Kelly RJ, Hillmen P (2013) Thrombosis in paroxysmal nocturnal hemoglobinuria Blood, 121(25): pp. 4985-96; quiz 5105 Hill A, Kelly RJ, Hillmen P (2013) Thrombosis in paroxysmal nocturnal hemoglobinuria Blood, 121(25): pp. 4985-96; quiz 5105
38.
go back to reference Nagase K et al (2012) Extensive cutaneous ulcerations and necrosis associated with paroxysmal nocturnal hemoglobinuria. Arch Dermatol 148(5):660–662PubMedCrossRef Nagase K et al (2012) Extensive cutaneous ulcerations and necrosis associated with paroxysmal nocturnal hemoglobinuria. Arch Dermatol 148(5):660–662PubMedCrossRef
39.
40.
go back to reference Warkentin TE et al (2005) Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 127(5):1857–1861PubMedCrossRef Warkentin TE et al (2005) Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 127(5):1857–1861PubMedCrossRef
41.
go back to reference Warkentin TE (2022) Platelet-activating anti-PF4 disorders: an overview. Semin Hematol 59(2):59–71PubMedCrossRef Warkentin TE (2022) Platelet-activating anti-PF4 disorders: an overview. Semin Hematol 59(2):59–71PubMedCrossRef
45.
go back to reference Lim W (2009) Antiphospholipid antibody syndrome. Hematol Am Soc Hematol Educ Program, : p. 233–239 Lim W (2009) Antiphospholipid antibody syndrome. Hematol Am Soc Hematol Educ Program, : p. 233–239
46.
go back to reference Barbhaiya M et al (2023) The 2023 ACR/EULAR antiphospholipid syndrome classification Criteria. Arthritis Rheumatol 75(10):1687–1702PubMedCrossRef Barbhaiya M et al (2023) The 2023 ACR/EULAR antiphospholipid syndrome classification Criteria. Arthritis Rheumatol 75(10):1687–1702PubMedCrossRef
47.
go back to reference Asherson RA et al (2006) The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol 24(1 Suppl 40):S46–51PubMed Asherson RA et al (2006) The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol 24(1 Suppl 40):S46–51PubMed
48.
go back to reference Schellong SM et al (1997) Classification of Sneddon’s syndrome. Vasa 26(3):215–221PubMed Schellong SM et al (1997) Classification of Sneddon’s syndrome. Vasa 26(3):215–221PubMed
49.
go back to reference Francès C et al (1999) Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Med (Baltim) 78(4):209–219CrossRef Francès C et al (1999) Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Med (Baltim) 78(4):209–219CrossRef
51.
go back to reference Wypasek E, Undas A (2013) Protein C and protein S deficiency - practical diagnostic issues. Adv Clin Exp Med 22(4):459–467PubMed Wypasek E, Undas A (2013) Protein C and protein S deficiency - practical diagnostic issues. Adv Clin Exp Med 22(4):459–467PubMed
52.
55.
go back to reference Wajih Z, Singer R (2022) Successful treatment of calciphylaxis with vitamin K in a patient on haemodialysis. Clin Kidney J 15(2):354–356PubMedCrossRef Wajih Z, Singer R (2022) Successful treatment of calciphylaxis with vitamin K in a patient on haemodialysis. Clin Kidney J 15(2):354–356PubMedCrossRef
56.
go back to reference Dobry AS et al (2018) Association between Hypercoagulable conditions and calciphylaxis in patients with renal disease: a case-control study. JAMA Dermatol 154(2):182–187PubMedCrossRef Dobry AS et al (2018) Association between Hypercoagulable conditions and calciphylaxis in patients with renal disease: a case-control study. JAMA Dermatol 154(2):182–187PubMedCrossRef
57.
go back to reference Ghosh T et al (2017) Early clinical presentations and progression of calciphylaxis. Int J Dermatol 56(8):856–861PubMedCrossRef Ghosh T et al (2017) Early clinical presentations and progression of calciphylaxis. Int J Dermatol 56(8):856–861PubMedCrossRef
58.
go back to reference Khalil S, Ariel Gru A, Saavedra AP (2019) Cutaneous extramedullary haematopoiesis: implications in human disease and treatment. Exp Dermatol 28(11):1201–1209PubMedCrossRef Khalil S, Ariel Gru A, Saavedra AP (2019) Cutaneous extramedullary haematopoiesis: implications in human disease and treatment. Exp Dermatol 28(11):1201–1209PubMedCrossRef
59.
go back to reference Cuthbert D, Stein BL (2019) Polycythemia Vera-Associated complications: Pathogenesis, Clinical manifestations, and effects on outcomes. J Blood Med 10:359–371PubMedPubMedCentralCrossRef Cuthbert D, Stein BL (2019) Polycythemia Vera-Associated complications: Pathogenesis, Clinical manifestations, and effects on outcomes. J Blood Med 10:359–371PubMedPubMedCentralCrossRef
60.
go back to reference Michiels JJ et al (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102(4):466–471PubMedCrossRef Michiels JJ et al (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102(4):466–471PubMedCrossRef
61.
go back to reference Siegel FP, Tauscher J, Petrides PE (2013) Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol 88(8):665–669PubMedCrossRef Siegel FP, Tauscher J, Petrides PE (2013) Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol 88(8):665–669PubMedCrossRef
62.
go back to reference Cozzani E et al (2015) Essential thrombocythemia: the dermatologic point of View. Clin Lymphoma Myeloma Leuk 15(12):739–747PubMedCrossRef Cozzani E et al (2015) Essential thrombocythemia: the dermatologic point of View. Clin Lymphoma Myeloma Leuk 15(12):739–747PubMedCrossRef
63.
go back to reference Itin PH, Winkelmann RK (1991) Cutaneous manifestations in patients with essential thrombocythemia. J Am Acad Dermatol 24(1):59–63PubMedCrossRef Itin PH, Winkelmann RK (1991) Cutaneous manifestations in patients with essential thrombocythemia. J Am Acad Dermatol 24(1):59–63PubMedCrossRef
64.
go back to reference Patel LM et al (2012) Myeloid leukemia cutis in the setting of myelodysplastic syndrome: a crucial dermatological diagnosis. Int J Dermatol 51(4):383–388PubMedCrossRef Patel LM et al (2012) Myeloid leukemia cutis in the setting of myelodysplastic syndrome: a crucial dermatological diagnosis. Int J Dermatol 51(4):383–388PubMedCrossRef
66.
go back to reference LeBlanc RE et al (2015) JAK2-positive cutaneous myelofibrosis presenting as sclerosing extramedullary hematopoietic tumors on the scalp: case presentation and review of the literature. J Cutan Pathol 42(11):858–862PubMedCrossRef LeBlanc RE et al (2015) JAK2-positive cutaneous myelofibrosis presenting as sclerosing extramedullary hematopoietic tumors on the scalp: case presentation and review of the literature. J Cutan Pathol 42(11):858–862PubMedCrossRef
67.
69.
go back to reference Dispenzieri A (2019) POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 94(7):812–827PubMedCrossRef Dispenzieri A (2019) POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 94(7):812–827PubMedCrossRef
70.
71.
72.
go back to reference Terrier B et al (2013) The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Med (Baltim) 92(2):61–68CrossRef Terrier B et al (2013) The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Med (Baltim) 92(2):61–68CrossRef
73.
go back to reference Harel S et al (2015) Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol 168(5):671–678PubMedCrossRef Harel S et al (2015) Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol 168(5):671–678PubMedCrossRef
74.
75.
go back to reference Cohen SJ, Pittelkow MR, Su WP (1991) Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. J Am Acad Dermatol 25(1 Pt 1):21–27PubMedCrossRef Cohen SJ, Pittelkow MR, Su WP (1991) Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of seventy-two patients. J Am Acad Dermatol 25(1 Pt 1):21–27PubMedCrossRef
77.
go back to reference Amdo TD, Welker JA (2004) An approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med 116(5):332–337PubMedCrossRef Amdo TD, Welker JA (2004) An approach to the diagnosis and treatment of cryofibrinogenemia. Am J Med 116(5):332–337PubMedCrossRef
78.
go back to reference Kaltoft B et al (2013) Primary localised cutaneous amyloidosis–a systematic review. Dan Med J 60(11):A4727PubMed Kaltoft B et al (2013) Primary localised cutaneous amyloidosis–a systematic review. Dan Med J 60(11):A4727PubMed
79.
go back to reference Muchtar E et al (2021) Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med 289(3):268–292PubMedCrossRef Muchtar E et al (2021) Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med 289(3):268–292PubMedCrossRef
80.
go back to reference Weidner T, Illing T, Elsner P (2017) Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol 18(5):629–642PubMedCrossRef Weidner T, Illing T, Elsner P (2017) Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol 18(5):629–642PubMedCrossRef
81.
go back to reference Afrin LB et al (2016) Often seen, rarely recognized: mast cell activation disease–a guide to diagnosis and therapeutic options. Ann Med 48(3):190–201PubMedCrossRef Afrin LB et al (2016) Often seen, rarely recognized: mast cell activation disease–a guide to diagnosis and therapeutic options. Ann Med 48(3):190–201PubMedCrossRef
82.
go back to reference Valent P et al (2022) Mast cell activation syndromes: Collegium Internationale Allergologicum Update 2022. Int Arch Allergy Immunol 183(7):693–705PubMedCrossRef Valent P et al (2022) Mast cell activation syndromes: Collegium Internationale Allergologicum Update 2022. Int Arch Allergy Immunol 183(7):693–705PubMedCrossRef
84.
go back to reference Krystel-Whittemore M, Dileepan KN, Wood JG (2016) Mast cell: a multi-functional Master cell. Front Immunol, 6 Krystel-Whittemore M, Dileepan KN, Wood JG (2016) Mast cell: a multi-functional Master cell. Front Immunol, 6
85.
go back to reference Jackson CW et al (2021) Mastocytosis and mast cell activation disorders: Clearing the Air. Int J Mol Sci, 22(20) Jackson CW et al (2021) Mastocytosis and mast cell activation disorders: Clearing the Air. Int J Mol Sci, 22(20)
86.
go back to reference Valent P et al (2022) Global classification of mast cell activation disorders: an ICD-10-CM-Adjusted proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract 10(8):1941–1950PubMedCrossRef Valent P et al (2022) Global classification of mast cell activation disorders: an ICD-10-CM-Adjusted proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract 10(8):1941–1950PubMedCrossRef
87.
88.
go back to reference Pardanani A (2023) Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol 98(7):1097–1116PubMedCrossRef Pardanani A (2023) Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol 98(7):1097–1116PubMedCrossRef
90.
go back to reference Lange M et al (2013) Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol 27(1):97–102PubMedCrossRef Lange M et al (2013) Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol 27(1):97–102PubMedCrossRef
91.
go back to reference Di Raimondo C et al (2021) Cutaneous mastocytosis: a dermatological perspective. Australas J Dermatol 62(1):e1–e7PubMedCrossRef Di Raimondo C et al (2021) Cutaneous mastocytosis: a dermatological perspective. Australas J Dermatol 62(1):e1–e7PubMedCrossRef
92.
go back to reference Berezowska S et al (2014) Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol 27(1):19–29PubMedCrossRef Berezowska S et al (2014) Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol 27(1):19–29PubMedCrossRef
93.
go back to reference Hartmann K et al (2016) Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 137(1):35–45PubMedCrossRef Hartmann K et al (2016) Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 137(1):35–45PubMedCrossRef
94.
go back to reference Armstrong CA (2012) 444 - examination of the skin and Approach to diagnosing skin diseases. Goldman’s Cecil Medicine (Twenty Fourth Edition). W.B. Saunders, Philadelphia, pp 2503–2509. L. Goldman and A.I. Schafer, Editors Armstrong CA (2012) 444 - examination of the skin and Approach to diagnosing skin diseases. Goldman’s Cecil Medicine (Twenty Fourth Edition). W.B. Saunders, Philadelphia, pp 2503–2509. L. Goldman and A.I. Schafer, Editors
95.
go back to reference Prose NS, Antaya RJ (2008) Chap. 25 - Neoplastic and Infiltrative Diseases, in Neonatal Dermatology (Second Edition), L.F. Eichenfield, I.J. Frieden, and N.B. Esterly, Editors. W.B. Saunders: Edinburgh. pp. 461–476 Prose NS, Antaya RJ (2008) Chap. 25 - Neoplastic and Infiltrative Diseases, in Neonatal Dermatology (Second Edition), L.F. Eichenfield, I.J. Frieden, and N.B. Esterly, Editors. W.B. Saunders: Edinburgh. pp. 461–476
96.
go back to reference Brockow K et al (2003) Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 48(4):508–516PubMedCrossRef Brockow K et al (2003) Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 48(4):508–516PubMedCrossRef
97.
98.
go back to reference Khoury JD et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36(7):1703–1719PubMedPubMedCentralCrossRef Khoury JD et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36(7):1703–1719PubMedPubMedCentralCrossRef
99.
100.
go back to reference Krooks J, Minkov M, Weatherall AG (2018) Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol 78(6):1035–1044PubMedCrossRef Krooks J, Minkov M, Weatherall AG (2018) Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol 78(6):1035–1044PubMedCrossRef
101.
go back to reference Ehrhardt MJ et al (2014) The natural history of skin-limited Langerhans cell histiocytosis: a single-institution experience. J Pediatr Hematol Oncol 36(8):613–616PubMedCrossRef Ehrhardt MJ et al (2014) The natural history of skin-limited Langerhans cell histiocytosis: a single-institution experience. J Pediatr Hematol Oncol 36(8):613–616PubMedCrossRef
102.
go back to reference Li Z et al (2010) Two case report studies of Langerhans cell histiocytosis with an analysis of 918 patients of Langerhans cell histiocytosis in literatures published in China†. Int J Dermatol 49(10):1169–1174PubMedCrossRef Li Z et al (2010) Two case report studies of Langerhans cell histiocytosis with an analysis of 918 patients of Langerhans cell histiocytosis in literatures published in China†. Int J Dermatol 49(10):1169–1174PubMedCrossRef
103.
go back to reference St Claire K et al (2020) Langerhans cell histiocytosis: a great imitator. Clin Dermatol 38(2):223–234PubMedCrossRef St Claire K et al (2020) Langerhans cell histiocytosis: a great imitator. Clin Dermatol 38(2):223–234PubMedCrossRef
104.
go back to reference Rivera-Luna R et al (1988) Langerhans cell histiocytosis: clinical experience with 124 patients. Pediatr Dermatol 5(3):145–150PubMedCrossRef Rivera-Luna R et al (1988) Langerhans cell histiocytosis: clinical experience with 124 patients. Pediatr Dermatol 5(3):145–150PubMedCrossRef
105.
go back to reference Mataix J et al (2008) Nail changes in Langerhans cell histiocytosis: a possible marker of multisystem disease. Pediatr Dermatol 25(2):247–251PubMedCrossRef Mataix J et al (2008) Nail changes in Langerhans cell histiocytosis: a possible marker of multisystem disease. Pediatr Dermatol 25(2):247–251PubMedCrossRef
106.
go back to reference Ashena Z et al (2007) Nail involvement in langerhans cell histiocytosis. Pediatr Hematol Oncol 24(1):45–51PubMedCrossRef Ashena Z et al (2007) Nail involvement in langerhans cell histiocytosis. Pediatr Hematol Oncol 24(1):45–51PubMedCrossRef
107.
go back to reference Haroche J, Cohen-Aubart F, Amoura Z (2020) Erdheim-Chester Disease Blood 135(16):1311–1318PubMed Haroche J, Cohen-Aubart F, Amoura Z (2020) Erdheim-Chester Disease Blood 135(16):1311–1318PubMed
108.
go back to reference Kobic A et al (2020) Erdheim–Chester disease: expanding the spectrum of cutaneous manifestations. Br J Dermatol 182(2):405–409PubMedCrossRef Kobic A et al (2020) Erdheim–Chester disease: expanding the spectrum of cutaneous manifestations. Br J Dermatol 182(2):405–409PubMedCrossRef
109.
go back to reference Hernandez-Martin A et al (1997) Juvenile xanthogranuloma. J Am Acad Dermatol, 36(3 Pt 1): p. 355 – 67; quiz 368-9. Hernandez-Martin A et al (1997) Juvenile xanthogranuloma. J Am Acad Dermatol, 36(3 Pt 1): p. 355 – 67; quiz 368-9.
110.
go back to reference So N, Liu R, Hogeling M (2020) Juvenile xanthogranulomas: examining single, multiple, and extracutaneous presentations. Pediatr Dermatol 37(4):637–644PubMedCrossRef So N, Liu R, Hogeling M (2020) Juvenile xanthogranulomas: examining single, multiple, and extracutaneous presentations. Pediatr Dermatol 37(4):637–644PubMedCrossRef
111.
go back to reference Dehner LP (2003) Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 27(5):579–593PubMedCrossRef Dehner LP (2003) Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 27(5):579–593PubMedCrossRef
112.
go back to reference Song M et al (2011) Structural correlations between dermoscopic and histopathological features of juvenile xanthogranuloma. J Eur Acad Dermatol Venereol 25(3):259–263PubMedCrossRef Song M et al (2011) Structural correlations between dermoscopic and histopathological features of juvenile xanthogranuloma. J Eur Acad Dermatol Venereol 25(3):259–263PubMedCrossRef
113.
go back to reference Weitzman S, Jaffe R (2005) Uncommon histiocytic disorders: the non-langerhans cell histiocytoses. Pediatr Blood Cancer 45(3):256–264PubMedCrossRef Weitzman S, Jaffe R (2005) Uncommon histiocytic disorders: the non-langerhans cell histiocytoses. Pediatr Blood Cancer 45(3):256–264PubMedCrossRef
114.
115.
go back to reference Kolde G, Bonsmann G (1992) Generalized lichenoid juvenile xanthogranuloma. Br J Dermatol 126(1):66–70PubMedCrossRef Kolde G, Bonsmann G (1992) Generalized lichenoid juvenile xanthogranuloma. Br J Dermatol 126(1):66–70PubMedCrossRef
116.
go back to reference Torrelo A et al (2009) Multiple lichenoid juvenile xanthogranuloma. Pediatr Dermatol 26(2):238–240PubMedCrossRef Torrelo A et al (2009) Multiple lichenoid juvenile xanthogranuloma. Pediatr Dermatol 26(2):238–240PubMedCrossRef
117.
go back to reference Caputo R et al (2007) Unusual variants of non-langerhans cell histiocytoses. J Am Acad Dermatol 57(6):1031–1045PubMedCrossRef Caputo R et al (2007) Unusual variants of non-langerhans cell histiocytoses. J Am Acad Dermatol 57(6):1031–1045PubMedCrossRef
118.
go back to reference Kaur MR et al (2008) Disseminated clustered juvenile xanthogranuloma: an unusual morphological variant of a common condition. Clin Exp Dermatol 33(5):575–577PubMedCrossRef Kaur MR et al (2008) Disseminated clustered juvenile xanthogranuloma: an unusual morphological variant of a common condition. Clin Exp Dermatol 33(5):575–577PubMedCrossRef
119.
go back to reference Boyd A et al (2016) Molluscum Mimicker: Juvenile Xanthogranulomas with Associated Juvenile Myelomonocytic Leukemia. J Pediatr 177:326–326e1PubMedCrossRef Boyd A et al (2016) Molluscum Mimicker: Juvenile Xanthogranulomas with Associated Juvenile Myelomonocytic Leukemia. J Pediatr 177:326–326e1PubMedCrossRef
120.
go back to reference Tamir I et al (2013) Solitary juvenile xanthogranuloma mimicking intracranial tumor in children. J Clin Neurosci 20(1):183–188PubMedCrossRef Tamir I et al (2013) Solitary juvenile xanthogranuloma mimicking intracranial tumor in children. J Clin Neurosci 20(1):183–188PubMedCrossRef
121.
go back to reference De Paula AM et al (2010) Solitary, extracutaneous, skull-based juvenile xanthogranuloma. Pediatr Blood Cancer 55(2):380–382PubMedCrossRef De Paula AM et al (2010) Solitary, extracutaneous, skull-based juvenile xanthogranuloma. Pediatr Blood Cancer 55(2):380–382PubMedCrossRef
122.
go back to reference Karami R et al (2019) Rosai-Dorfman Disease: cutaneous and parotid involvement. Ann Plast Surg 82(6):639–641PubMedCrossRef Karami R et al (2019) Rosai-Dorfman Disease: cutaneous and parotid involvement. Ann Plast Surg 82(6):639–641PubMedCrossRef
123.
go back to reference Levine PH et al (1992) Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Infect Dis 166(2):291–295PubMedCrossRef Levine PH et al (1992) Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J Infect Dis 166(2):291–295PubMedCrossRef
124.
125.
go back to reference Bruce-Brand C, Schneider JW, Schubert P (2020) Rosai-Dorfman disease: an overview. J Clin Pathol 73(11):697–705PubMedCrossRef Bruce-Brand C, Schneider JW, Schubert P (2020) Rosai-Dorfman disease: an overview. J Clin Pathol 73(11):697–705PubMedCrossRef
126.
go back to reference Kong YY et al (2007) Cutaneous rosai-dorfman disease: a clinical and histopathologic study of 25 cases in China. Am J Surg Pathol 31(3):341–350PubMedCrossRef Kong YY et al (2007) Cutaneous rosai-dorfman disease: a clinical and histopathologic study of 25 cases in China. Am J Surg Pathol 31(3):341–350PubMedCrossRef
127.
go back to reference Zhang Y, Chen H (2019) Image Gallery: generalized cutaneous Rosai-Dorfman disease presenting as acneiform lesions. Br J Dermatol 180(2):e36PubMedCrossRef Zhang Y, Chen H (2019) Image Gallery: generalized cutaneous Rosai-Dorfman disease presenting as acneiform lesions. Br J Dermatol 180(2):e36PubMedCrossRef
128.
go back to reference El-Kamel MF, Selim MK, Gawad MMA (2020) A new presentation of isolated cutaneous Rosai-Dorfman disease: eruptive xanthoma-like lesions. Indian J Dermatol Venereol Leprol 86(2):158–161PubMedCrossRef El-Kamel MF, Selim MK, Gawad MMA (2020) A new presentation of isolated cutaneous Rosai-Dorfman disease: eruptive xanthoma-like lesions. Indian J Dermatol Venereol Leprol 86(2):158–161PubMedCrossRef
129.
go back to reference Fening K et al (2010) Cutaneous rosai-dorfman disease persisting after surgical excision: report of a case treated with acitretin. J Clin Aesthet Dermatol 3(9):34–36PubMedPubMedCentral Fening K et al (2010) Cutaneous rosai-dorfman disease persisting after surgical excision: report of a case treated with acitretin. J Clin Aesthet Dermatol 3(9):34–36PubMedPubMedCentral
130.
go back to reference Wickramasinghe SN, Porwit A, Erber WN (2011) CHAPTER 2 - Normal bone marrow cells: Development and cytology, in Blood and Bone Marrow Pathology (Second Edition), A. Porwit, J. McCullough, and W.N. Erber, Editors. Churchill Livingstone: Edinburgh. pp. 19–44 Wickramasinghe SN, Porwit A, Erber WN (2011) CHAPTER 2 - Normal bone marrow cells: Development and cytology, in Blood and Bone Marrow Pathology (Second Edition), A. Porwit, J. McCullough, and W.N. Erber, Editors. Churchill Livingstone: Edinburgh. pp. 19–44
131.
go back to reference Chaín M et al (2004) Cutaneous true histiocytic malignancy: True histiocytic lymphoma Journal of the American Academy of Dermatology, 50(2, Supplement): pp. 9–10 Chaín M et al (2004) Cutaneous true histiocytic malignancy: True histiocytic lymphoma Journal of the American Academy of Dermatology, 50(2, Supplement): pp. 9–10
133.
go back to reference Marshall ME, Farmer ER, Trump DL (1981) Cutaneous involvement in malignant histiocytosis: Case Report and Review of the literature. Arch Dermatol 117(5):278–281PubMedCrossRef Marshall ME, Farmer ER, Trump DL (1981) Cutaneous involvement in malignant histiocytosis: Case Report and Review of the literature. Arch Dermatol 117(5):278–281PubMedCrossRef
134.
go back to reference Morgan NE et al (1983) Clinical and pathologic cutaneous manifestations of malignant histiocytosis. Arch Dermatol 119(5):367–372PubMedCrossRef Morgan NE et al (1983) Clinical and pathologic cutaneous manifestations of malignant histiocytosis. Arch Dermatol 119(5):367–372PubMedCrossRef
135.
go back to reference Zerah ML, DeWitt CA (2015) Cutaneous findings in Hemophagocytic Lymphohistiocytosis. Dermatology 230(3):234–243PubMedCrossRef Zerah ML, DeWitt CA (2015) Cutaneous findings in Hemophagocytic Lymphohistiocytosis. Dermatology 230(3):234–243PubMedCrossRef
136.
go back to reference Handler NS et al (2017) Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol 56(6):e106–e117PubMedCrossRef Handler NS et al (2017) Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol 56(6):e106–e117PubMedCrossRef
137.
go back to reference Schulenburg-Brand D et al (2014) The cutaneous porphyrias. Dermatol Clin, 32(3): p. 369 – 84, ix. Schulenburg-Brand D et al (2014) The cutaneous porphyrias. Dermatol Clin, 32(3): p. 369 – 84, ix.
138.
go back to reference Shah A, Bhatt H (2023) Cutanea Tarda Porphyria, in StatPearls. StatPearls Publishing Shah A, Bhatt H (2023) Cutanea Tarda Porphyria, in StatPearls. StatPearls Publishing
139.
go back to reference Copyright (2023) © StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Harshil Bhatt declares no relevant financial relationships with ineligible companies Copyright (2023) © StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Harshil Bhatt declares no relevant financial relationships with ineligible companies
Metadata
Title
Dermatologic manifestations of hematologic disorders
Authors
Hannah L. King
Genevieve B. Benedetti
Jesse J. Keller
Thomas G. DeLoughery
Joseph J. Shatzel
Kylee L. Martens
Publication date
25-04-2024
Publisher
Springer Berlin Heidelberg
Keyword
Petechiae
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05761-5
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare